These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Overactive bladder: a clinical entity or a marketing hype? Madersbacher H Eur Urol; 2005 Mar; 47(3):273-6. PubMed ID: 15716186 [No Abstract] [Full Text] [Related]
6. [In overactive bladder, above all urgency is stressful. The patients know the site of each toilet]. MMW Fortschr Med; 2004 May; 146(22):51. PubMed ID: 15373116 [No Abstract] [Full Text] [Related]
7. Solifenacin in the management of the overactive bladder syndrome. Robinson D; Cardozo L Int J Clin Pract; 2005 Oct; 59(10):1229-36. PubMed ID: 16178992 [TBL] [Abstract][Full Text] [Related]
8. [Therapeutic strategy and impact of new treatments]. Haab F Ann Urol (Paris); 2005 Dec; 39 Suppl 6():S188-91. PubMed ID: 16440495 [No Abstract] [Full Text] [Related]
9. [Treatment of overactive bladder]. Hunskår S Tidsskr Nor Laegeforen; 2005 Aug; 125(15):2029-30. PubMed ID: 16100546 [No Abstract] [Full Text] [Related]
10. Neurophysiology of micturition and pharmacotherapy of lower urinary tract dysfunction. Cerruto ; Pesce F; Artibani W Diabetes Nutr Metab; 2002 Feb; 15(1):28-41. PubMed ID: 11942736 [No Abstract] [Full Text] [Related]
11. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Hegde SS; Mammen M; Jasper JR Curr Opin Investig Drugs; 2004 Jan; 5(1):40-9. PubMed ID: 14983972 [TBL] [Abstract][Full Text] [Related]
12. Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. Lazzeri M Eur Urol; 2009 Mar; 55(3):737-8. PubMed ID: 18502027 [No Abstract] [Full Text] [Related]
13. Anticholinergic drugs for overactive bladder. Kripke C Am Fam Physician; 2006 Jan; 73(1):66. PubMed ID: 16417066 [No Abstract] [Full Text] [Related]
14. [Treatment of overactive bladder]. Schiøtz H Tidsskr Nor Laegeforen; 2005 Sep; 125(18):2525-6; author reply 2526. PubMed ID: 16186882 [No Abstract] [Full Text] [Related]
15. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Gallegos PJ; Frazee LA Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115 [TBL] [Abstract][Full Text] [Related]
16. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed? Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055 [TBL] [Abstract][Full Text] [Related]
17. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Kuo HC Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967 [TBL] [Abstract][Full Text] [Related]
18. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Hay-Smith J; Herbison P; Ellis G; Moore K Cochrane Database Syst Rev; 2002; (3):CD003781. PubMed ID: 12137711 [TBL] [Abstract][Full Text] [Related]
19. The evaluation and treatment of female urinary incontinence--a comparison of clinical practice in the Republic of Ireland with the recommendations of the International Continence Society. Agnew G; Byrne P Ir Med J; 2004 Sep; 97(8):238-40. PubMed ID: 15532970 [TBL] [Abstract][Full Text] [Related]